Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll

June 13, 2013

Myriad Genetics Trial: Your Thoughts?

The U.S. Supreme Court just delivered a mixed decision for companies looking to patent human genes, ruling against Myriad Genetics’ patent claims for breast cancer susceptibility genes BRCA 1 and 2, but also holding that companies can patent composite DNA (cDNA) and other synthetic genetic material that does not meet the “product of nature” exemption from patentability. How do you feel about this?

Do you agree with the Supreme Court’s decision in the Myriad case?

  {{ choice.Percent }}%